Medical technology company Okami Medical announced on Wednesday that it has received approval from the US FDA for an expanded indication of its LOBO Vascular Occlusion System.
The expanded indication extends the use of LOBO into peripheral veins, expanding embolisation options for patients with venous conditions such as pelvic venous disease and portal hypertension.
The LOBO device, a novel embolisation system, is designed to offer physicians fast, reliable occlusion with controlled, mechanical precision across a wide range of peripheral vessel anatomies. It is based on Okami's proprietary HDBRAID construction, engineered to optimise deliverability, occlusivity, and stability for efficient procedures.
Asker Healthcare Group acquires Estonia's Teresa OÜ
Abbott's Amulet 360 shows high LAA closure rates and low stroke incidence at one year
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
Abbott secures CE Mark for Cologuard Plus in Europe
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
SciBase technology selected as primary endpoint in NIH-led skin exposure study
TWINBIRD launches portable freezer targeting dry-ice-free research cold chains
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder